

## Carlo Conti

### Partner

Carlo Conti is a partner in the field of life sciences and health law. He advises institutions and organizations on questions of life sciences and health law and on matters of governmental and administrative law. He is a member of a number of boards of directors. He is also a lecturer on health law at the University of Basel law school and regularly speaks at national and international conferences.

He has many years of professional experience and deep knowledge of all areas of life sciences and health law, as well as governmental and administrative law. He held executive positions in the pharmaceutical industry for more than 15 years. Carlo Conti then served as member of the State Council for Basel-Stadt Canton where he was head of the public health department. He was also president of the Swiss Conference of Public Health Ministers and chairman of the board of Swiss DRG AG and vice-chairman of the agency council of Swissmedic.

### Practice Areas:

Life Sciences and Health Law  
Constitutional and Administrative Law  
Corporate and Commercial

### Functions:

Lecturer in health law at the University of Basel  
Chairman of Basel Tourismus  
Numerous mandates as President or  
Member of the Board of Directors of various companies  
Board Member of various organisations

### Career:

2016	Partner Wenger Plattner
2014	Counsel Wenger Plattner
2000	Member and Vice-President of the Cantonal Government Basel-Stadt, Head of the Department of Public Health
1985	F. Hoffmann-La Roche AG, in senior management position Legal Department and Public Relations
1985	University of Basel (Dr. iur.)
1982	Attorney at Law
1978	University of Basel (lic. iur.)

### Selected publications:

- *Kommentar zu Art. 16a - 16c HMG*  
In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022



### Contact

Dr. Carlo Conti  
Attorney at Law  
Wenger Plattner  
Attorneys at Law Tax Advisors Public  
Notaries  
Aeschenvorstadt 55  
4010 Basel

T +41 61 279 70 00  
F +41 61 279 70 01  
[carlo.conti@wenger-plattner.ch](mailto:carlo.conti@wenger-plattner.ch)

### Admission:

Bar admission (1982)

### Languages:

German, English, Italian, French

- *GLI - Pricing & Reimbursement 2021*  
GLI - Pricing & Reimbursement 2021, Fourth Edition, p. 195 - 204
- *GLI - Pricing & Reimbursement 2020*  
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and must satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.
- *The Pharma Legal Handbook Switzerland*  
Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms | Pharma Board Room, London 2020
- *GLI - Pricing & Reimbursement 2019*  
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and has to satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.
- *GLI - Pricing & Reimbursement 2018*  
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are in principle granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare.
- *Versorgungsmanagement im Spannungsfeld zwischen Daten-, Patientenschutz und sektoralen Versorgungsgrenzen (in German)*  
In: Versorgungsmanagement in Gesundheitssystemen, Rebscher Herbert / Kaufmann Stefan (Hrsg.), Heidelberg 2013, S. 139 ff.